Amedis Pharmaceuticals Ltd.
Amedis Pharmaceuticals Ltd., based in Cambridge, UK, has developed a range of tools designed to help overcome the bottleneck in the drug development process. Established in April 2000, teh company has devised two core platform technologies based on a combination of chemistry, biology and bioinformatics.
You may also be interested in...
Thanks to high throughput screening, more than 10,000 compounds with biological activity against specific targets are entering the drug discovery process each week. But unless those compounds can pass the hurdles of bioavailability and safety, comprising a series of tests known as ADMET (for absorption, metabolism, distribution, elimination and toxicity), they will never be successful drugs. Today, the tests that make up ADMET evaluation are low throughput, and are apparently not informative or accurate enough to predict a drug's probability of success, given the high failure rate of compounds at all stages of development. Drug discovery companies are therefore looking to re-engineer the ADMET process, moving it up the early discovery chain. The goal is to predict, very early in the process, perhaps even before compounds are synthesized, which compounds pass the test for a good drug. Doing so will require new assays, new computer models, and large volumes of consistent, high quality data on drugs in man, across diverse sets of chemistries. No one company has it all; partnerships and consortiums aim to bring together the necessary resources to integrate absorption, metabolism, and toxicity into a single platform.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.